Grants and Contributions:
Title:
Development of a plant-based candidate combination vaccine for SARS-CoV-2 and seasonal influenza
Agreement Number:
920200
Agreement Value:
$1,915,000.00
Agreement Date:
Jan 1, 2019 - Mar 31, 2023
Description:
Development of a plant-derived candidate universal influenza vaccine ready for clinical development
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1V 3V9
Reference Number:
172-2018-2019-Q4-920200
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
872308499
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is -600,000 dollars.
Amendment Date
Jun 1, 2022
Recipient's Legal Name:
Medicago Inc.
Federal Riding Name:
Louis-Hébert
Federal Riding Number:
24044
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: